SCHEMBL6200513

SCHEMBL6200513

CC(=O)OC1Cc2ccc(N)cc2C1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.42
ESR1 P03372 1/20 0.42
HSD17B10 Q99714 1/20 0.42
NR1H2 P55055 1/20 0.40
PSEN1 P49768 1/20 0.39
PSEN2 P49810 1/20 0.39
APH1B Q8WW43 1/20 0.39
NCSTN Q92542 1/20 0.39
APH1A Q96BI3 1/20 0.39
PSENEN Q9NZ42 1/20 0.39
HSD17B3 P37058 1/20 0.38
FABP7 O15540 2/20 0.37
FABP5 Q01469 2/20 0.37
MMP8 P22894 8/20 0.37
MMP3 P08254 4/20 0.37
CA1 P00915 4/20 0.36
CA2 P00918 4/20 0.36
CA12 O43570 3/20 0.36
CA7 P43166 3/20 0.36
CA14 Q9ULX7 3/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28972016 0.85 PSEN1 (0.40) ALDH1A1HSD17B10NR1H2PSEN1PSEN2
SCHEMBL7909110 0.84 PSEN1 (0.40) ALDH1A1NR1H2PSEN1PSEN2APH1B
SCHEMBL28381288 0.81 SLC6A4 (0.42) PSEN1PSEN2APH1BNCSTNAPH1A
SCHEMBL30493157 0.80 PNMT (0.42) HSD17B3
SCHEMBL1197541 0.80 PNMT (0.42) HSD17B3
SCHEMBL3725001 0.80 MAPT (0.51) ALDH1A1ESR1HSD17B10
SCHEMBL16127116 0.80 PNMT (0.36) FABP7FABP5CA1CA2CA12
SCHEMBL30493000 0.78 FABP7 (0.50) FABP7FABP5FABP3
SCHEMBL1196934 0.78 FABP7 (0.50) FABP7FABP5FABP3
SCHEMBL19726331 0.78 AKT1 (0.36)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1259484-B1 CARBOXAMIDES USEFUL AS INHIBITORS OF MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN AND OF APOLIPOPROTEIN B SECRETION NOVARTIS AG (CH) 2005-05-18 EP disclosed
US-6878707-B2 Carboxamides useful as inhibitors of microsomal triglyceride transfer protein and of apolipoprotein b secretion NOVARTIS AG (CH) 2005-04-12 US disclosed
US-20030109700-A1 Carboxamides useful as inhinitors of microsomal triglyceride transfer protein and of apolipoprotein b secretion NOVARTIS AG (CH) 2003-06-12 US disclosed
EP-1259484-A1 CARBOXAMIDES USEFUL AS INHIBITORS OF MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN AND OF APOLIPOPROTEIN B SECRETION Novartis AG (CH) 2002-11-27 EP disclosed
WO-2001053260-A1 CARBOXAMIDES USEFUL AS INHIBITORS OF MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN AND OF APOLIPOPROTEIN B SECRETION NOVARTIS AG (CH) 2001-07-26 WO disclosed
US-3943149-A HYPOCHOLESTEREMIC, ANTIINFLAMMATORY E. R. SQUIBB & SONS, INC. (US) 1976-03-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030109700-A1 Carboxamides useful as inhinitors of microsomal triglyceride transfer protein and of apolipoprotein b secretion APOB, CETP, MTTP ALDH1A1 1969/4885ESR1 2751/4885HSD17B10 114/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.